Ke Ding

15.0k total citations · 2 hit papers
332 papers, 10.8k citations indexed

About

Ke Ding is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Ke Ding has authored 332 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 200 papers in Molecular Biology, 85 papers in Oncology and 81 papers in Organic Chemistry. Recurrent topics in Ke Ding's work include Cancer therapeutics and mechanisms (34 papers), Protein Degradation and Inhibitors (34 papers) and Lung Cancer Treatments and Mutations (29 papers). Ke Ding is often cited by papers focused on Cancer therapeutics and mechanisms (34 papers), Protein Degradation and Inhibitors (34 papers) and Lung Cancer Treatments and Mutations (29 papers). Ke Ding collaborates with scholars based in China, United States and Thailand. Ke Ding's co-authors include Xiaoyun Lu, Xiaomei Ren, Zhang Zhang, Shaomeng Wang, Jeff B. Smaill, Qian Cai, Jingxuan Pan, Zhengchao Tu, Zaneta Nikolovska‐Coleska and Fengtao Zhou and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Ke Ding

318 papers receiving 10.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 Interaction

2006 602 citations Ke Ding, Yipin Lu et al. Journal of Medicinal Chemistry profile →
Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors

2005 564 citations Ke Ding, Yipin Lu et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ke Ding	5.4k	3.7k	2.3k	945	665	332	10.8k
John A. Hartley	7.2k 1.3×	3.3k 0.9×	4.0k 1.7×	564 0.6×	1.2k 1.8×	293	10.9k
Takao Yamori	7.7k 1.4×	1.9k 0.5×	2.4k 1.0×	719 0.8×	1.3k 1.9×	241	11.7k
Lloyd R. Kèlland	8.1k 1.5×	4.3k 1.2×	7.0k 3.0×	1.1k 1.1×	1.3k 1.9×	176	15.3k
William G. Bornmann	7.7k 1.4×	2.9k 0.8×	3.6k 1.5×	860 0.9×	1.5k 2.2×	167	14.7k
Bruce C. Baguley	9.1k 1.7×	3.8k 1.0×	4.3k 1.8×	623 0.7×	1.9k 2.9×	384	15.0k
Nouri Neamati	6.0k 1.1×	3.5k 0.9×	1.4k 0.6×	452 0.5×	874 1.3×	241	12.1k
Thomas Meyer	3.7k 0.7×	1.2k 0.3×	2.2k 0.9×	887 0.9×	668 1.0×	137	7.9k
Lucia Altucci	9.9k 1.8×	1.1k 0.3×	2.1k 0.9×	672 0.7×	1.5k 2.2×	321	14.5k
Eranthie Weerapana	5.6k 1.0×	2.7k 0.7×	1.2k 0.5×	289 0.3×	498 0.7×	128	9.3k
Gregory D. Cuny	6.9k 1.3×	1.9k 0.5×	1.3k 0.5×	750 0.8×	839 1.3×	165	11.5k

Countries citing papers authored by Ke Ding

Since Specialization

Citations

This map shows the geographic impact of Ke Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke Ding more than expected).

Fields of papers citing papers by Ke Ding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ke Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke Ding. The network helps show where Ke Ding may publish in the future.

Co-authorship network of co-authors of Ke Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Ke Ding. A scholar is included among the top collaborators of Ke Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ke Ding. Ke Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Shengrong, Liyan Huang, Zhengchao Tu, et al.. (2024). Catalyst-free late-stage functionalization to assemble α-acyloxyenamide electrophiles for selectively profiling conserved lysine residues. Communications Chemistry. 7(1). 31–31. 10 indexed citations

Xiao, Jijun, Ke Ding, Tingting Zhang, et al.. (2024). Regulation of histidine metabolism by Lactobacillus Reuteri mediates the pathogenesis and treatment of ischemic stroke. Acta Pharmaceutica Sinica B. 15(1). 239–255. 4 indexed citations

Gong, Xiaocheng, Yunfei Liu, Keying Liang, et al.. (2024). Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization. Biochemical and Biophysical Research Communications. 738. 150508–150508. 3 indexed citations

Zhang, Ziqiang, et al.. (2024). Protective effect of selenomethionine on rabbit testicular injury induced by Aflatoxin B1. The Science of The Total Environment. 927. 171973–171973. 7 indexed citations

Ran, Ke, Yang Zhou, Shaohua Chang, et al.. (2024). Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor. European Journal of Medicinal Chemistry. 272. 116473–116473. 4 indexed citations

Meng, Qingyuan, Weixue Huang, Meiru Song, et al.. (2024). Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors. Journal of Medicinal Chemistry. 67(8). 6099–6118. 4 indexed citations

Liu, Wenyan, Yu Bai, Licheng Zhou, et al.. (2023). Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia. European Journal of Medicinal Chemistry. 264. 115974–115974. 13 indexed citations

Kim, Tae Hoon, Hye Jeong Oh, In‐Hye Ham, et al.. (2023). Targeting GAS6/AXL signaling improves the response to immunotherapy by restoring the anti-immunogenic tumor microenvironment in gastric cancer. Life Sciences. 335. 122230–122230. 3 indexed citations

Li, Chungen, Yuanyuan Qiao, Xia Jiang, et al.. (2023). Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve. Journal of Medicinal Chemistry. 66(17). 12432–12445. 10 indexed citations

10.

Mao, Liufeng, Lijie Peng, Xiaomei Ren, et al.. (2022). Discovery of JND003 as a New Selective Estrogen-Related Receptor α Agonist Alleviating Nonalcoholic Fatty Liver Disease and Insulin Resistance. PubMed. 2(3). 282–296. 7 indexed citations

11.

Zhang, Zhen, et al.. (2020). A patent review of discoidin domain receptor 1 (DDR1) modulators (2014-present). Expert Opinion on Therapeutic Patents. 30(5). 341–350. 13 indexed citations

12.

Ti, Huihui, Yang Zhou, Xue Liang, et al.. (2019). Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). Journal of Medicinal Chemistry. 62(13). 5944–5978. 22 indexed citations

13.

Aguilera, Kristina Y., Huocong Huang, Wenting Du, et al.. (2017). Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics. 16(11). 2473–2485. 88 indexed citations

14.

Chang, Yu, Xiaoyun Lu, Marthandam Asokan Shibu, et al.. (2017). Structure Based Design of N-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides as Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors. Journal of Medicinal Chemistry. 60(13). 5927–5932. 20 indexed citations

15.

Jin, Bei, Chengyan Wang, Juan Li, et al.. (2016). Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clinical Cancer Research. 23(3). 789–803. 53 indexed citations

16.

Jin, Bei, Ke Ding, & Jingxuan Pan. (2014). Ponatinib Induces Apoptosis in Imatinib-Resistant Human Mast Cells by Dephosphorylating Mutant D816V KIT and Silencing β-Catenin Signaling. Molecular Cancer Therapeutics. 13(5). 1217–1230. 36 indexed citations

17.

Wu, Yongbin, Xiaoyong Sun, Xianping Shi, et al.. (2012). Cyclin-Dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor α and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells. Clinical Cancer Research. 18(7). 1966–1978. 42 indexed citations

18.

Gao, Yu, Huaping Dai, Xuefeng Xu, & Ke Ding. (2011). Inhibition of TGF-β1-induced extracellular matrix production in primary human pulmonary fibroblasts by rapamycin. European Respiratory Journal. 38(Suppl 55). p2006–p2006. 1 indexed citations

19.

Jin, Yanli, Zhongzheng Lu, Ke Ding, et al.. (2010). Antineoplastic Mechanisms of Niclosamide in Acute Myelogenous Leukemia Stem Cells: Inactivation of the NF-κB Pathway and Generation of Reactive Oxygen Species. Cancer Research. 70(6). 2516–2527. 261 indexed citations

20.

Shangary, Sanjeev, Ke Ding, Su Qiu, et al.. (2008). Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Molecular Cancer Therapeutics. 7(6). 1533–1542. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact